Peps
What is Larazotide?
Larazotide is an investigational peptide studied for persistent symptoms in celiac disease. The featured trial kept participants on a gluten-free diet.
Biological role or research focus
Celiac disease symptom research.
A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.
Role reference: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗
Names you may encounter
Larazotide acetate
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Investigational tight-junction regulator peptide
- Research focus
- Celiac disease symptom research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Molecular structure
How Larazotide works
The proposed approach concerns regulation of intestinal tight junctions. A barrier-related hypothesis is not proof of a general treatment for conditions described as “leaky gut.”
Clinical context & research status
The study examined adults with celiac disease and persistent symptoms despite a gluten-free diet. It did not test replacing that diet or unrestricted gluten intake.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2015
Larazotide celiac-disease phase 2 trial
Did persistent celiac symptoms improve while participants maintained a gluten-free diet?
- Population / model
- 342 adults with celiac disease and persistent symptoms after at least 12 months on a gluten-free diet.
- Study design
- Randomized double-blind placebo-controlled 12-week trial with run-in and follow-up periods; three active-treatment groups.
- Main finding
- One active-treatment group met the primary symptom endpoint; the other two did not show improvement on that endpoint. Safety was comparable with placebo during the trial.
- Limits & context
- A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection. ↗
European heart journal · 2023 Apr 7 · Journal Article, Research Support, Non-U.S. Gov't
Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. ↗
Nature communications · 2020 Apr 24 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments. ↗
Nutrients · 2025 Sep 15 · Journal Article, Review
Read available full text ↗
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration. ↗
Gut · 2026 Mar 6 · Journal Article, Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Comparable short-term adverse-event rates do not establish long-term safety or benefit in people without celiac disease.
Identity, route, and evidence limits
A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
2 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Dr. Jones, DC
Larazotide - The Missing Gut Peptide #guthealing #inflammation ↗
Title match · Captions not indexed
Dr. Jones, DC
Larazotide Fixes Leaky Gut #guthealth #peptides ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Could larazotide replace a gluten-free diet?
- What population, comparator, and route were actually studied?
- A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Could larazotide replace a gluten-free diet?
This trial maintained the gluten-free diet. Its findings cannot establish that larazotide makes gluten exposure safe.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.